

NOW APPROVED
FIRST AND ONLY
FDA-APPROVED EoE
TREATMENT
IN CHILDREN AGES 1-11 YEARS WITH
EOSINOPHILIC ESOPHAGITIS (EoE)



EoE IS A CHRONIC AND PROGRESSIVE CONDITION

EoE can get worse over time, resulting in ongoing damage to the esophagus.



DISCOVER A BREAKTHROUGH TREATMENT FOR CHILDREN WITH EoE

As an innovative treatment, DUPIXENT is now available to treat children as young as 1 year old who weigh at least 33 pounds (15 kg).

Patients saw a significant reduction of inflammation in 4 months*:

- DUPIXENT reduced eosinophils in the esophagus, which contribute to inflammation
- Visible improvements of the esophagus were seen in people treated with DUPIXENT

It was observed that as early as 4 months, children taking DUPIXENT had fewer days with EoE signs and symptoms than before treatment. A similar improvement was also seen at 1 year.*†



SEE WHAT'S DIFFERENT

- DUPIXENT targets an underlying source of inflammation, which can cause EoE
- DUPIXENT is not a steroid or immunosuppressant
- DUPIXENT is an injectable treatment given under the skin (subcutaneous injection)
- Dose and frequency of DUPIXENT depends on child's weight



KNOW THE MOST COMMON SIDE EFFECTS

The most common side effects in pediatric patients with EoE include injection site reactions, upper respiratory tract infections, cold sores in your mouth or on your lips, and joint pain (arthralgia). For additional details, see Important Safety Information below.



GET SUPPORT FROM *DUPIXENT MyWay*[®]

DUPIXENT MyWay offers support, answers to your treatment and insurance questions, and a dedicated support team to help you get started and stay on track with your prescribed treatment plan.



Scan to visit [DUPIXENT.com](https://www.dupilumab.com), or call
1-844-DUPIXENT (1-844-387-4936), option 1
to learn more about *DUPIXENT MyWay*.

*Results from 61 patients ages 1 to 11 years old (≥33 lbs) with EoE in a two-part study.

†As measured by the Pediatric EoE Sign/Symptom Questionnaire-Caregiver (PESQ-C).

INDICATION

DUPIXENT is a prescription medicine used to treat adults and children 1 year of age and older with eosinophilic esophagitis (EoE), who weigh at least 33 pounds (15 kg). It is not known if DUPIXENT is safe and effective in children with eosinophilic esophagitis under 1 year of age, or who weigh less than 33 pounds (15 kg).

Please see additional Important Safety Information for DUPIXENT on next page.

Please see accompanying full [Prescribing Information](#) including [Patient Information](#).

IMPORTANT SAFETY INFORMATION

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.

Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

- have a parasitic (helminth) infection.
- are scheduled to receive any vaccinations. You should not receive a “live vaccine” right before and during treatment with DUPIXENT.
- are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby.
 - A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby. To enroll or get more information call 1-877-311-8972 or go to <https://mothertobaby.org/ongoing-study/dupixent/>.
- are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines or if you have EoE and asthma and use an asthma medicine. **Do not** change or stop your corticosteroid medicine or other asthma medicine without talking to your healthcare provider. This may cause other symptoms that were controlled by the corticosteroid medicine or other asthma medicine to come back.

DUPIXENT can cause serious side effects, including:

- **Allergic reactions. DUPIXENT can cause allergic reactions that can sometimes be severe.** Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, joint pain, general ill feeling, itching, skin rash, swollen lymph nodes, nausea or vomiting, or cramps in your stomach-area.
- **Joint aches and pain.** Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms.

The most common side effects in patients with eosinophilic esophagitis include injection site reactions, upper respiratory tract infections, cold sores in your mouth or on your lips, and joint pain (arthralgia).

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. **Do not** try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it’s recommended DUPIXENT be administered by or under supervision of an adult. In children 1 to less than 12 years of age, DUPIXENT should be given by a caregiver.

Please see accompanying full Prescribing Information including Patient Information.

sanofi | **REGENERON**®

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
DUPIXENT® and DUPIXENT MyWay® are registered trademarks of
Sanofi Biotechnology. DUP.23.08.0429 1/2024

DUPIXENT®
(dupilumab) Injection
200mg • 300mg